Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia

The manufacturer of ceftolozane with tazobactam anticipates that it will be used in line with good antimicrobial stewardship, on the advice of a microbiologist, to treat critically ill ventilated adults with HAP and VAP, who are deteriorating or not responding to initial antibiotic therapy, and who have confirmed or highly suspected Pseudomonas aeruginosa. Specialists involved in producing this evidence summary consider that ceftolozane with tazobactam provides a potentially useful alternative for treating some adults with HAP and VAP who have limited treatment options because they have infections suspected or proven to be caused by caused by Enterobacterales (excluding carbapenem-resistant bacteria) or multidrug-resistant Pseudomonas aeruginosa. Local antibiotic resistance patterns will need to be taken into account.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news